Prognostic value of serum anti-heat-shock protein 70 and paraoxonase levels in idiopathic sudden sensorineural hearing loss

Yıl 2014, Cilt: 24 Sayı: 2, 83 - 88, 20.04.2014

Sertaç Düzer Hayrettin Cengiz Alpay Dilara Kaman Öner Sakallıoğlu Şinasi Yalçın İrfan Kaygusuz Turgut Karlıdağ Erol Keleş

Öz

Objectives: This study aims to investigate the correlation between serum anti-heat-shock protein 70 anti-HSP 70 levels, serum paraoxonase PON levels and prognosis of idiopathic sudden sensorineural hearing loss ISSHL . Patients and Methods: Twenty-five patients with ISSHL as the study group and 25 healthy volunteers as the control group were enrolled in this study. Blood samples were obtained from all patients before the treatment initiation and on the 10th day of the treatment from only patients of the study group. Idiopathic sudden sensorineural hearing loss was defined as the hearing loss between 250-6.000 Hz frequencies. The recoveries in the hearing thresholds were evaluated at 10 days of the treatment. Results: When the pre-treatment serum PON, anti-HSP 70 levels and the post-treatment serum PON, anti-HSP 70 levels of the patients with ISSHL were compared, we observed that the post-treatment serum PON levels of the recovered patients increased, while the post-treatment serum anti-HSP 70 levels of recovered patients decreased. Conclusion: We believe that serum levels of anti-HSP 70 and PON can be used as markers for estimating and evaluating the prognosis of ISSHL patients.

Anahtar Kelimeler

Heat-shock protein 70, idiopathic sudden sensorineural hearing loss, paraoxonase, prognosis

İdiyopatik ani sensörinöral işitme kaybında anti-ısı-şok protein 70 ve paraoksonaz serum düzeylerinin prognostik değeri

Öz

Amaç: Bu çalışmada serum anti-ısı-şok protein 70 anti-IŞP 70 düzeyleri ve serum paraoksonaz PON düzeyleri ve idiyopatik ani sensörinöral işitme kaybı İASNİK prognozu arasındaki ilişki araştırıldı.Hastalar ve Yöntemler: Çalışmaya 25 İASNİK’li hasta çalışma grubu olarak ve 25 sağlıklı gönüllü kontrol grubu olarak dahil edildi. Tüm hastalardan tedaviye başlamadan önce ve yalnızca çalışma grubundaki hastalardan tedavinin 10. gününde kan örneği alındı. İdiyopatik ani sensörinöral işitme kaybı, 250-6.000 Hz arasındaki işitme kaybı olarak tanımlandı. Tedavinin 10. gününde işitmede düzelme olup olmadığı değerlendirildi.Bulgular: Tedavi öncesi serum PON ve anti-IŞP 70 düzeyleri tedavi sonrası serum PON ve anti-IŞP 70 düzeyleri ile karşılaştırıldığında, iyileşen hastalarda tedavi sonrası serum PON düzeylerinin arttığı, yine iyileşen hastalarda tedavi sonrası anti-IŞP 70 serum düzeylerinin ise azaldığı belirlendi.Sonuç: Anti-IŞP 70 ve PON serum düzeylerinin, İASNİK’li hastalarda prognozu tahmin etmede ve değerlendirmede kullanılabileceğini düşünmekteyiz

Anahtar Kelimeler

Isı şok protein 70, idiyopatik sensörinöral ani işitme kaybı, paraoksonaz, prognoz

Kaynakça

• Byl FM Jr. Sudden hearing loss: eight years' experience and suggested prognostic table. Laryngoscope 1984;94:647-61.
• Mattox DE, Simmons FB. Natural history of sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 1977;86:463-80.
• Harris JP, Sharp PA. Inner ear autoantibodies in patients with rapidly progressive sensorineural hearing loss. Laryngoscope 1990;100:516-24.
• Bloch DB, Gutierrez JA, Guerriero V Jr, Rauch SD, Bloch KJ. Recognition of a dominant epitope in bovine heat- shock protein 70 in inner ear disease. Laryngoscope 1999;109:621-5.
• Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995;15:1812-8.
• Heijmans BT, Westendorp RG, Lagaay AM, Knook DL, Kluft C, Slagboom PE. Common paraoxonase gene variants, mortality risk and fatal cardiovascular events in elderly subjects. Atherosclerosis 2000;149:91-7.
• Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan- Starck TC, Harmony JA. Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 1994;33:832-9.
• Hasselwander O, McMaster D, Fogarty DG, Maxwell AP, Nicholls DP, Young IS. Serum paraoxonase and platelet-activating factor acetylhydrolase in chronic renal failure. Clin Chem 1998;44:179-81.
• Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:1233-8.
• McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986;32:671-3.
• Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol 1998;31:329-36.
• Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 2000;101:2510-7.
• Fortunato G, Marciano E, Zarrilli F, Mazzaccara C, Intrieri M, Calcagno G, et al. Paraoxonase and superoxide dismutase gene polymorphisms and noise- induced hearing loss. Clin Chem 2004;50:2012-8.
• Siegel LG. The treatment of idiopathic sudden sensorineural hearing loss. Otolaryngol Clin North Am 1975;8:467-73.
• Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet 1983;35:214-27.
• Booth JB. Sudden and fluctuant sensorineural hearing loss. In: Kerr AG, editor. Scott Brown’s Otolaryngology. 6th ed. London: Butterworths-Heinemann 1997. p. 1-82.
• Gong SS, Yan Z. Expression of heat shock protein 70 in the cochlea in experimental autoimmune inner ear disease. Ann Otol Rhinol Laryngol 2002;111:275-80.
• Mathews J, Rao S, Kumar BN. Autoimmune sensorineural hearing loss: is it still a clinical diagnosis? J Laryngol Otol 2003;117:212-4.
• Loveman DM, de Comarmond C, Cepero R, Baldwin DM. Autoimmune sensorineural hearing loss: clinical course and treatment outcome. Semin Arthritis Rheum 2004;34:538-43.
• Süslü N, Yilmaz T, Gürsel B. Utility of anti-HSP 70, TNF-alpha, ESR, antinuclear antibody, and antiphospholipid antibodies in the diagnosis and treatment of sudden sensorineural hearing loss. Laryngoscope 2009;119:341-6.
• Park SN, Yeo SW, Park KH. Serum heat shock protein 70 and its correlation with clinical characteristics in patients with sudden sensorineural hearing loss. Laryngoscope 2006;116:121-5.
• Gross M, Eliashar R, Ben-Yaakov A, Ulmansky R, Elidan J. Prevalence and clinical significance of anticardiolipin, anti-beta2-glycoprotein-1, and anti- heat shock protein-70 autoantibodies in sudden sensorineural hearing loss. Audiol Neurootol 2008;13:231-8.
• bin Ali A, Zhang Q, Lim YK, Fang D, Retnam L, Lim SK. Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. Free Radic Biol Med 2003;34:824-9.
• Biasioli S, Schiavon R, Petrosino L, De Fanti E, Cavalcanti G, Battaglia P, Fasolin A. Paraoxonase activity and paraoxonase 1 gene polymorphism in patients with uremia. ASAIO J 2003;49:295-9.
• Seres I, Paragh G, Deschene E, Fulop T Jr, Khalil A. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 2004;39:59-66.